Regenerative medicine firm Plasticell has appointed Dr Aaron Chuang as chief scientific officer.
Chuang joins from GlaxoSmithKline, where he served as research director at the regenerative medicine unit for over 18 years. Chuang initiated the first stem cell drug discovery programme at GSK in 2004 and was central in the firm’s stem cell R&D.
Commenting on his appointment, Chuang said: “I am delighted to be joining Plasticell, especially as I have followed closely the company and its innovative technologies for well over 10 years.”
Chuang was an industrial advisor on high profile stem cell initiatives including UK Stem Cell Initiative, UK Cell Therapy Catapult and the California Institute of Regenerative Medicine.
He was also prominent in establishing GSK’s alliance with the Harvard Stem Cell Institute in 2008 and coordinated all collaborative projects.
Dennis Saw, CEO at Plasticell, said: “I am delighted to welcome Aaron to the management team. His scientific background, product development experience and understanding of the industry will be invaluable as we further develop our cell therapy pipeline and expand our network of collaborators.”